N-Dodecyl-Na(2)-1H-indol-5-ylurea | 950184-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-Dodecyl-Na(2)-1H-indol-5-ylurea
• 英文别名: 1-dodecyl-3-(1H-indol-5-yl)urea
• CAS: 950184-32-4
• 化学式: C₂₁H₃₃N₃O
• 分子量: 343.5
• InChiKey: MEFMJSLQAFETMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  56.9
• 氢给体数：
  3
• 氢受体数：
  1

文献信息

• CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
  申请人：Hammock D. Bruce

  公开号：US20070225283A1

  公开（公告）日：2007-09-27

  Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

  提供了可抑制可溶性环氧化物水解酶（sEH）的抑制剂，这些抑制剂结合了多种药效团，并且在治疗疾病方面具有用途。
• US8188289B2
  申请人：——

  公开号：US8188289B2

  公开（公告）日：2012-05-29
• US8501783B2
  申请人：——

  公开号：US8501783B2

  公开（公告）日：2013-08-06
• US9029550B2
  申请人：——

  公开号：US9029550B2

  公开（公告）日：2015-05-12
• [EN] PIPERIDINYL, INDOLYL, PIRINIDYL, MORPHOLINYL AND BENZIMIDAZOLYL UREA DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE FOR THE TREATMENT OF HYPERTENSION, INFLAMMATIONS AND OTHER DISEASES<br/>[FR] INHIBITEURS D'UREE A CONFORMATION RESTREINTE D'EPOXYDE HYDROLASE SOLUBLE
  申请人：UNIV CALIFORNIA

  公开号：WO2007106525A1

  公开（公告）日：2007-09-20

  [EN] Compounds of the formula (I); wherein R¹ is a member selected from the group consisting of C₁-C₈alkyl, arylC₀-C₈alkyl, C₃-C₁₂cycloalkyl and heterocyclyl, Y¹ is selected from the group consisting of a bond, C(R⁵)₂, NR⁵ and O; Y² is selected from the group consisting of a bond, NR⁵ and O; each R², R³ and R⁵ is independently selected from the group consisting of H, alkyl and COR⁶; A is heterocyclyl, optionally substituted with from 1 to 2 R⁷ substituents; L is selected from the group consisting of a direct bond, C₁-C₁₂alkylene, C_1-C₁₂heteroalkylene, C₃-C₆cycloalkylene, arylene, heteroarylene, -CO-, -SO_in- and -Se-; R⁴ is selected from the group consisting of H, C₁C₈alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₁,-C₈heteroalkyl, arylC₀-C₈alkyl, C₃C,₁₂cycloalkyl and heterocyclyl, are claimed. The compounds are inhibitors of the soluble epoxide hydrolase (sEH) and useful for the treatment of hypertension, inflammation, adult respiratory distress syndrome; diabetic complications; end stage renal disease; Raynaud syndrome and arthritis.
  [FR] La présente invention concerne des inhibiteurs d'époxyde hydrolase soluble (sEH) qui comprennent plusieurs pharmacophores et qui sont utiles dans le traitement de maladies.